42
|
125
|
7p6vAAA |
N-terminal bromodomain of human brd4 with compound 3ag |
40
|
126
|
7p6yAAA |
N-terminal bromodomain of human brd4 with compound 5ef |
49
|
134
|
7p4sA |
Bromodomain of human taf1 (2) with naphthyridinone compound |
40
|
127
|
7p6wAAA |
N-terminal bromodomain of human brd4 with compound 3bg |
44
|
112
|
7oetAAA |
C-terminal bromodomain of human brd2 with 1,5-dimethyl-n-(2-(methylamino)-2-oxo-1-(tetrahydro-2h-pyran-4-yl)ethyl)-6-oxo-n-(2-phenyl-2-(pyridin-2-yl)ethyl)-1,6-dihydropyridine-3-carboxamide |
42
|
124
|
7o18AAA |
N-terminal bromodomain of human brd4 with i-bet282 |
40
|
126
|
7mceA |
Crystal structure of the first bromodomain of human brd4 in complex with 2-{(7p)-7-(1,4-dimethyl-1h-1,2,3-triazol-5-yl)-8-fluoro-5-[(s)-(oxan-4-yl)(phenyl)methyl]-5h-pyrido[3,2-b]indol-3-yl}propan-2-ol |
57
|
133
|
7m98A |
Atad2 bromodomain complexed with histone h4k5ac (res 1-10) ligand |
44
|
123
|
7m16A |
Triazole-based bet family bromodomain inhibitor bound to brd4(d1) |
38
|
110
|
7lhyA |
Caenorhabditis elegans swsn-4 (smarca4-brg1) atpase bromodomain in complex with a modified histone h3, n6-epsilon-acetyl-l-lysine 14 (h3k14ac) polypeptide |
44
|
122
|
7lajA |
Crystal structure of the first bromodomain (bd1) of human brd2 bound to ro3280 |
36
|
108
|
7lauA |
Crystal structure of the first bromodomain (bd1) of human brd2 bound to erk5-in-1 |
41
|
121
|
7lahA |
Crystal structure of the first bromodomain (bd1) of human brd2 bound to bromosporine |
99
|
252
|
7k6fA |
Crystal structure of the tandem bromodomain (bd1, bd2) of human taf1 in complex with mes (2-(n-morpholino)ethanesulfonic acid) |
41
|
127
|
7k6hA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to xmd8-92 |
41
|
127
|
7k6gA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to erk5-in-1 |
48
|
123
|
7k42A |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to dioxane |
49
|
123
|
7k3oA |
Crystal structure of the unliganded second bromodomain (bd2) of human taf1 |
102
|
248
|
7k03A |
Crystal structure of the tandem bromodomain (bd1 and bd2) of human taf1 bound to atr kinase inhibitor azd6738 |
101
|
250
|
7k0dA |
Crystal structure of the tandem bromodomain (bd1, bd2) of human taf1 bound to mtorc1/2 inhibitor azd3147 |
39
|
113
|
7juoA |
Cbp bromodomain complexed with yf2-23 |
52
|
130
|
7k1pA |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to bromosporine |
55
|
137
|
7jjgA |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to atr kinase inhibitor az20 |
54
|
128
|
7k0uA |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to plk1 kinase inhibitor bi2536 |
41
|
127
|
7jkyA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with yf3-126 |
98
|
247
|
7k27A |
Crystal structure of the tandem bromodomain (bd1, bd2) of human taf1 bound to atr inhibitor az20 |
58
|
135
|
7jtcA |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to zs1-322 |
55
|
137
|
7jspA |
Crystal structure of the second bromodomain (bd2) of human taf1 bound to atr kinase inhibitor azd6738 |
42
|
127
|
7jkwA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with zn1-99 |
40
|
111
|
7jkzA |
Bromodomain-containing protein 4 (brd4) bromodomain 2 (bd2) complexed with yf3-126 |
47
|
129
|
7dhsA |
Crystal structure analysis of the brd4 |
35
|
108
|
7bjyA |
Crystal structure of the first bromodomain (bd1) of human brdt bound to ro3280 |
42
|
127
|
7axrA |
Crystal structure of brd4(1) bound to the dual bet-hdac inhibitor lsh24 |
43
|
126
|
6wvxA |
Crystal structure of the first bromodomain of human brd4 with benzodiazepine inhibitor |
42
|
120
|
7laiA |
Crystal structure of the first bromodomain (bd1) of human brd2 bound to bi2536 |
42
|
126
|
5s9rA |
Crystal structure of the first bromodomain of human brd4 in complex with bms-986158, 2-{3-(1,4-dimethyl-1h-1,2,3-triazol-5-yl)-5-[(s)-(oxan-4-yl)(phenyl)methyl]-5h-pyrido[3,2-b]indol-7-yl}propan-2-ol |
44
|
127
|
5s9qA |
Crystal structure of the first bromodomain of human brd4 in complex with 2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9-[(s)-(oxan-4-yl)(phenyl)methyl]-9h-carbazole-4-carboxamide |
38
|
121
|
5s9oA |
Crystal structure of the human brd2 bd1 bromodomain in complex with 9-(cyclopropylmethyl)-7-[(2r,6s)-2,6-dimethylmorpholine-4-carbonyl]-3-(3,5-dimethyl-1,2-oxazol-4-yl)-9h-carbazole-1-carboxamide |
43
|
128
|
5s9pA |
Crystal structure of the first bromodomain of human brd4 in complex with 9-benzyl-2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9h-carbazole-4-carboxamide |
43
|
127
|
7remA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor pn1-050 |
44
|
125
|
7rekA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor ma9-086 |
45
|
127
|
7relA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor ma9-060 |
44
|
111
|
7ogyAAA |
C-terminal bromodomain of human brd2 with 1-benzyl-n5-cyclopropyl-n3-methyl-1h-pyrazole-3,5-dicarboxamide |
42
|
113
|
7oe4AAA |
C-terminal bromodomain of human brd2 with n-methyl-4-propionyl-1h-pyrrole-2-carboxamide |
43
|
111
|
7oe6AAA |
C-terminal bromodomain of human brd2 with n4-hydroxycyclohexyl-n2-methyl-5-phenylethyl-furan-2,4-dicarboxamide |
42
|
110
|
7oe5AAA |
C-terminal bromodomain of human brd2 with n5-hydroxycyclohexyl-n3-methyl-1-phenylethyl-1h-pyrazole-3,5-dicarboxamide |
41
|
110
|
7oe9A |
C-terminal bromodomain of human brd2 with rac-n5-((1r,5s)-3-oxabicyclo[3.1.0]hexan-6-yl)-n7,3-dimethyl-3-phenyl-2,3-dihydrobenzofuran-5,7-dicarboxamide |
44
|
112
|
7oe8A |
C-terminal bromodomain of human brd2 with n5-((1r,5s,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-3-(1h-indol-4-yl)-n7-methyl-2,3-dihydrobenzofuran-5,7-dicarboxamide |
42
|
113
|
7nq3AAA |
C-terminal bromodomain of human brd2 with n4-((1r,5s,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-6-((s)-methoxy(phenyl)methyl)-n2-methylpyridine-2,4-dicarboxamide |
42
|
113
|
7nq1AAA |
C-terminal bromodomain of human brd2 with 6-((s)-hydroxy(phenyl)methyl)-n2-methyl-n4-((1s,2s)-2-methylcyclopropyl)pyridine-2,4-dicarboxamide |